Coronavirus (COVID-19)
Learn more
March 13, 2013
Location: The Hospital of Central Connecticut
A Randomized Phase II Evaluation of Single-Agent Bevacizumab and Combination Bevacizumab with Fosbretabulin Thromethamine in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma (Platinum Sensitive and Platinum Resistant are eligible-NO Refractory patients).
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209